Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug
In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the US Food and Drug Administration (FDA) seeking approval to market generic versions of Ibrance.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Legislation | New Drug Applications | Pfizer | Pharmaceuticals